Show results for
Refine by
Antigen Targeting Suppliers Serving Ireland
40 companies found
based inVancouver, BRITISH COLUMBIA (CANADA)
STEMCELL Technologies provides high-quality cell culture media, cell separation technologies, instruments, accessory products, and educational resources to scientists around the world working on stem cell, immunology, cancer, regenerative medicine, ...
based inShanghai, CHINA
Focusing on the core raw materials of the life science industry, Yeasen Biotechnology (Shanghai) Co., Ltd. is a biotechnology company engaged in the research and development, production and sales of three major categories of biological reagents: ...
based inMons, BELGIUM
D-tek s.a. is a private Belgian biotechnology company created in 1995 in Mons (40 km from Brussels and less than 1h20 from Paris). The company is located in 1.200 square meters facilities in the Scientific Park Initialis of Mons. The company is ...
The M2 antibodies belong to the group of Anti-Mitochondrial Antibodies (AMA) and are strongly associated with PBC. At least 9 distinct AMA have been identified, which have been classified M1-M9 according to their antigen specificity and disease ...
based inYokohama, JAPAN
MabGenesis Inc. is a biopharmaceutical startup that uses 30+ years of antibody research to provide first-in-class and best-in-class therapeutic monoclonal antibody drugs for humans and animals. We have the world’s highest quality antibody libraries ...
based inSan Diego, CALIFORNIA (USA)
Founded originally in Vancouver, British Columbia in 2006 by three enthusiastic entrepreneurs passionate about providing the best biological reagents worldwide, MyBiosource, Inc. was incorporated as a company with big visions. Since 2007, we have ...
Product Gene Name: ADP elisa kit. Research Use Only: For Research Use Only. Not for use in diagnostic ...
based inVancouver, BRITISH COLUMBIA (CANADA)
Zymeworks Inc. is a publicly listed (NYSE: ZYME), clinical-stage, biopharmaceutical company dedicated to the discovery, development, and commercialization of next-generation multifunctional biotherapeutics, initially focused on the treatment of ...
in a single, transferable, conditionally active design. Right Place at the Right Time. With PROgrammed Tumor Engagement & Checkpoint/Co-stimulation Targeting, the ProTECT platform delivers multifunctional tumor-specific activity while ...
based inCoelbe, GERMANY
Convergent Technologies is an emerging leader in the field of Integrated Healthcare Solutions. We strive to provide innovative and cost-effective healthcare solutions enabling people live healthier lives. Our state-of-the-art diagnostic test and ...
The Convergys® COVID-19 Rapid Antigen Test is designed for the direct testing for acute COVID-19 infections. The rapid chromatographic immunoassay detects the Nucleocapsid protein of SARS-CoV-2, the pathogen causing the COVID-19 disease. Results ...
based inKrakow, POLAND
We are one of the largest preclinical contract research organizations in Europe, driven by a clear mission: to offer a comprehensive scope of services bridging the gap between early drug discovery and the clinical stage of drug development. We have ...
Cell and Molecular Biology Department at Selvita performs In vitro comparative studies of biosimilar insulins and insulin analogs as well as battery of various therapeutic antibodies (e.g. TNFα, VEGF and HER2 inhibitors etc.). These studies ...
based inSan Francisco, CALIFORNIA (USA)
Icosagen is a research-driven contract research provider for biopharmaceutical and biotechnology industries that deftly adapts to market forces and current trends, and is always guided by the needs of its customers. The Group comprises four ...
based inCambridge, MASSACHUSETTS (USA)
Sumitomo Pharma Oncology, Inc. is a developer of novel cancer therapeutics based in the U.S. and a wholly owned subsidiary of Sumitomo Pharma Co., Ltd. This U.S. entity, together with the oncology research and development teams in Japan, Cancer ...
Immunotherapeutic cancer vaccines have generated a lot of interest from oncologists since it was discovered that immune activation can lead to a specific antitumor response.1 However, despite initial progress, most cancer vaccines have failed to ...
based inCarlton South, AUSTRALIA
Chimeric Therapeutics is a clinical stage cell therapy company focused on bringing the promise of cell therapy to life for more patients with cancer. We believe that cellular therapies have the promise to cure cancer not just delay disease ...
CHM 2101 (CDH17 CAR T) is an optimized 3rd generation CAR T cell therapy that is the first to target ...
based inNew Orleans, LOUISIANA (USA)
Our mission is to advance infectious disease diagnosis and improve patient care using novel diagnostic platforms that produces rapid and accurate results from patient samples. Our versatile platforms address critical needs for current infectious ...
To address these issues, NanoPin uses an antibody enrichment approach to capture species-specific biomarker peptides released upon trypsin digestion of the serum of infected individuals and employs mass spectrometry to identify these peptides with ...
based inWroclaw, POLAND
Pure Biologics is a biopharmaceutical company focused on the biological drug and non-systemic therapies discovery and development. We operate in the areas of immuno-oncology, autoimmunology, and rare neurological diseases, conducting research based ...
In cancer, a balance between immune system effector and regulatory cells becomes disturbed. Regulatory T cells inhibit the activity of effector cells, including NK cells, a process known as immunosuppression. The PB003 (PureActivator) project ...
based inGosselies, BELGIUM
SYnAbs was founded in 2015 as a Belgian spin-off of the Catholic University of Louvain (UCL), based on the work of Prof. Hervé Bazin, the inventor of the world's first rat myeloma cell line. SYnAbs' vision is to fill the gap on the marketplace for ...
Transmembrane proteins are probably the most complex and challenging antigens to target with monoclonal antibodies. Indeed, despite their strong presence in the animal kingdom and their implications in many ...
based inMadison, WISCONSIN (USA)
Through a lot of hard work, a license from the Wisconsin Alumni Research Foundation (WARF) and a desire to have an impact on human health, NeoClone was founded in 1999 by three University of Wisconsin scientists who recognized the need for better ...
NeoClone is a world-class custom antibody development company, having discovered hundreds of antibodies for our clients. But there are very difficult targets out there that hybridoma technology alone can't solve. So we added antibody phage display ...
based inSouth San Francisco, CALIFORNIA (USA)
At Twist Bioscience, we work in the service of customers who are changing the world for the better. In fields such as medicine, agriculture, industrial chemicals, and data storage, by using our synthetic DNA tools, our customers are developing ways ...
The human anti-ACE2 receptor antibodies exhibit high affinity to the ACE2 receptor indicating that they have the potential to be developed as blocking or competitive antibodies for therapeutic ...
based inAbingdon, UNITED KINGDOM
PsiOxus is a clinical-stage company redefining therapies for solid tumors with the goal of curing patients with cancer. Our clinically validated, systemically dosed T-SIGn® viral vector platform delivers tumor-localized production of combinations of ...
Our clinically validated T-SIGn® viral vector platform delivers multiple transgene payloads that re-program the tumor microenvironment of both primary and metastatic tumors. Our platform can integrate rationally designed synthetic agents to ...
based inShanghai, CHINA
Elpiscience is a clinical-stage biopharmaceutical company focused on developing next-generation immunotherapies to benefit cancer patients worldwide. Elpiscience has a robust pipeline of globally innovative cancer immunotherapies covering a wide ...
ES101 is a first-in-class tetravalent bispecific antibody targeting 4-1BB and PD-L1. It has a unique mechanism of action as 4-1BB activation is dependent on PD-L1 binding. 4-1BB is a T cell co-stimulatory receptor and is a compelling immune ...
based inLondon, UNITED KINGDOM
Treos Bio is a clinical stage company introducing a disruptive computational technology to change the paradigm of cancer immunotherapy development by resolving the dual challenges of patient and tumor heterogeneity. We use proprietary therapeutic ...
At TREOS we use knowledgebase and algorithm embedded in PASCal (Personal Antigen Selection Calculator) tool to develop personal cancer immunotherapies. PASCal supports the development of immunotherapies for single individuals and a population of ...
based inVictoria, BRITISH COLUMBIA (CANADA)
IPA (ImmunoPrecise Antibodies NASDAQ: IPA ) is a biotherapeutic research company that brings industry leading antibody discovery services and complex artificial intelligence technologies together - to lead its pharmaceutical partners into the era of ...